Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 3, pp 703–712

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results


    • Karmanos Cancer Institute
  • George R. BlumenscheinJr
    • The University of Texas M.D. Anderson Cancer Center
  • Roger B. Cohen
    • Fox Chase Cancer Center
  • Patricia M. LoRusso
    • Karmanos Cancer Institute
  • Noelle K. LoConte
    • University of Wisconsin Carbone Cancer Center
  • Sindy T. Kim
    • Pfizer Oncology, Clinical Development
  • Ana Ruiz-Garcia
    • Pfizer Oncology, Clinical Development
  • Richard C. Chao
    • Pfizer Oncology, Clinical Development
  • George Wilding
    • University of Wisconsin Carbone Cancer Center
Original Article

DOI: 10.1007/s00280-010-1536-1

Cite this article as:
Heath, E.I., Blumenschein, G.R., Cohen, R.B. et al. Cancer Chemother Pharmacol (2011) 68: 703. doi:10.1007/s00280-010-1536-1



To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin.


Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175–200 mg/m2) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles. Dose-limiting toxicities (DLTs) and adverse events (AEs) were evaluated to determine the MTD. Efficacy parameters were analyzed in patients with measurable disease.


Forty-three patients were enrolled (n = 25 Schedule 2/1; n = 18 CDD schedule). Across all doses, 6 DLTs were observed [grade 4 papilledema, grade 5 GI hemorrhage, grade 3 neutropenic infection, and grade 4 thrombocytopenia (n = 3)]. The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m2 and carboplatin AUC 6 mg min/ml. The MTD was not determined for the CDD schedule. Treatment-related AEs included neutropenia (77%), thrombocytopenia (56%), and fatigue (47%). Of 38 evaluable patients, 4 (11%) had partial responses and 12 (32%) had stable disease. PK data indicated an increase in maximum and total plasma exposures to sunitinib and its active metabolite when given with paclitaxel and carboplatin compared with sunitinib monotherapy.


Myelosuppression resulting in prolonged dose delays and frequent interruptions was observed, suggesting that this treatment combination is not feasible in the general cancer population.


SunitinibPhase ISolid tumorNSCLCAntiangiogenesisChemotherapy

Copyright information

© Springer-Verlag 2010